Testosterone therapy as a novel approach to the management of cytopenias in myelodysplastic neoplasms: a review of literature and case report.

A patient with intermediate-risk myelodysplastic neoplasm and hypogonadism treated with testosterone replacement therapy showed sustained improvement in anemia.

• The patient showed sustained improvement in anemia with testosterone therapy
• The patient reported subjective improvement in weakness and fatigue
• Improvement occurred even in the setting of an undetectable follow-up erythropoietin level
• Testosterone levels showed marked improvement after therapy
• Repeat prostate specific antigen levels remained low after therapy

Testosterone, PSA, and erythropoietin levels were measured at baseline and 3 months after therapy initiation, with blood counts monitored over time.

• Testosterone, prostate specific antigen, and erythropoietin levels were checked prior to therapy initiation and 3 months after
• Blood counts were monitored over time
• The case involved a patient with intermediate-risk myelodysplastic neoplasm and hypogonadism

A literature review demonstrated positive response rates for testosterone in treating myelodysplastic neoplasm-related cytopenias.

• The literature review demonstrated positive response rates for testosterone in treating MDS-related cytopenias
• The review covered testosterone use in myelodysplastic neoplasm and the prevalence of hypogonadism in hematologic malignancies
• The authors concluded that use of testosterone in low and intermediate-risk MDS is underexplored

The literature review showed a higher incidence of hypogonadism in hematologic malignancies.

• The review showed a higher incidence of hypogonadism in hematologic malignancies
• The incidence of hypogonadism in myelodysplastic neoplasm and its potential impact on exacerbating cytopenias warrants further investigation according to the authors
• The link between hypogonadism and hematologic malignancies was a primary focus of the review

The authors concluded that testosterone poses significant potential as a future therapeutic agent in low and intermediate-risk myelodysplastic neoplasm after careful consideration of risks and benefits.

• The review suggests that the use of testosterone in low and intermediate-risk MDS is underexplored
• Testosterone therapy poses to have significant potential as a future therapeutic agent after careful consideration of risks and benefits
• The authors noted that the incidence of hypogonadism in MDS and its potential impact on exacerbating cytopenias warrants further investigation